LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
LifeMD, Inc.NASDAQ: LFMD
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns positive
Q1 FY2026 total equity was $15.04M, compared with -$392.75K a year earlier.
Context
- Total equity amounted to 21.4% of total assets at the end of Q1 FY2026, up 20.9 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +3928.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 23.16M USD
- Year-over-year change
- +672.4%
- 4-year CAGR
- -2.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.16M | +672.4% |
| FY2024 | 2024-12-31 | (4.05M) | -172.7% |
| FY2023 | 2023-12-31 | 5.57M | +176.2% |
| FY2022 | 2022-12-31 | (7.31M) | -128.3% |
| FY2021 | 2021-12-31 | 25.82M | — |
Total Equity vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +3928.6% is the highest of 10, against a peer median of -17.4%.
- Total equity amounts to 21.4% of total assets for LFMD, versus a peer median of 33.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $178.69M USD | +6.0% | -8.4% | 43.8% | |
| Mar 2026 | $134.17M USD | -15.8% | -9.0% | 71.9% | |
| Apr 2026 | CA$101.88M CAD | -28.2% | -14.1% | 29.3% | |
| Mar 2026 | $68.29M USD | +21.4% | -1.8% | 30.6% | |
| Mar 2026 | $64.92M USD | -17.4% | -11.7% | 65.8% | |
| Mar 2026 | $53.9M USD | -30.6% | -26.4% | 49.1% | |
| Mar 2026 | $34.34M USD | -2.4% | — | 33.4% | |
| Mar 2026 | $29.11M USD | -58.0% | -28.9% | 29.2% | |
| Mar 2026 | $15.04M USD | +3928.6% | — | 21.4% | |
| Mar 2026 | $7.02M USD | -80.9% | -47.8% | 10.1% | |
| Peer median (excluding LFMD) | — | -17.4% | -12.9% | 33.4% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41.33M | 3.96M | 33.15M | 35M | 36.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 980.06K | 2.83M | 5.28M | 8.22M | 9.31M |
| Inventory | 1.62M | 3.7M | 2.76M | 2.8M | 2.77M |
| Other Current Assets | 793.19K | 687.02K | 934.51K | 2.67M | 2.65M |
| Total Current Assets | 44.92M | 11.31M | 42.6M | 48.73M | 51.83M |
| Property, Plant & Equipment (Net) | 1.99M | 1.68M | 1.07M | 7.88M | 5.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.02M | 12.67M | 14.81M | 15.85M | 262.33K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 13.05M |
| Total Non-current Assets | 5M | 14.35M | 15.88M | 23.73M | 18.58M |
| Total Assets | 49.92M | 25.67M | 58.48M | 72.46M | 70.41M |
| Account Payables | 9.06M | 10.11M | 11.08M | 16.01M | 14.15M |
| Short-term Debt | 63.4K | 2.8M | 327.6K | 8.44M | 0 |
| Tax Payables | 2M | 2.5M | 2.5M | 2.27M | 0 |
| Deferred Revenue | 1.5M | 5.55M | 8.83M | 14.48M | 10.81M |
| Other Current Liabilities | 1.66M | 576.03K | 3M | 5.11M | 2.41M |
| Total Current Liabilities | 22.83M | 31.37M | 34.78M | 60.26M | 41.57M |
| Long-term Debt | 0 | 0 | 17.93M | 9.89M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 100K | 1.02M | 131.25K | 100K | 0 |
| Total Non-current Liabilities | 1.28M | 1.6M | 18.13M | 16.25M | 5.68M |
| Total Liabilities | 24.1M | 32.97M | 52.91M | 76.51M | 47.25M |
| Common Stock | 307.05K | 315.53K | 383.59K | 422.94K | 467.6K |
| Retained Earnings | (141.92M) | (190.56M) | (214.27M) | (236.25M) | (228.6M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (1.03M) | (475.55K) | 2.06M | 1.44M | 0 |
| Total Equity | 25.82M | (7.31M) | 5.57M | (4.05M) | 23.16M |
| Total Debt | 1.85M | 4.13M | 18.93M | 25.1M | 6.32M |
| Net Debt | (39.48M) | 168.52K | (14.21M) | (9.9M) | (30.46M) |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.